Sun Pharma to Acquire Organon in $11.75 Billion All-Cash Deal

Context Sun Pharma, a global pharmaceutical firm, has announced its agreement to purchase Organon & Co. Organon specializes in women's health, biosimilars, and established brands. This all-cash acquisition represents a strategic move to integrate Organon's diverse portfolio into Sun Pharma's operations, aiming to expand market reach and product offerings.

Key Facts Under the terms of the merger, Organon shareholders will receive $14.00 per share in cash. This valuation offers a 103% premium compared to Organon's unaffected closing price on April 9, 2026. The transaction establishes an implied enterprise value of $11.75 billion for Organon. Enterprise value reflects the total value of a company, encompassing both its market capitalization and its debt, less cash.

What It Means The merger agreement outlines specific conditions for its completion. Organon would incur a $120 million termination fee in certain scenarios, such as accepting a superior proposal. The agreement also includes standard no-shop clauses, limiting Organon's ability to solicit other acquisition bids, and fiduciary out clauses, which allow the board to consider better offers under specific legal duties. The deal's finalization depends on key conditions, including the requisite company vote and receiving necessary antitrust and foreign investment clearances from U.S. and non-U.S. regulators. Should the acquisition proceed, Organon will be delisted from the New York Stock Exchange and will no longer operate as an SEC reporting company. Regulatory review timelines and shareholder approval are now the primary elements to watch as this significant transaction progresses.